PPT-Safety and Efficacy of Uninterrupted Anticoagulation with

Dabigatran Etexilate versus Warfarin in Patients Undergoing Catheter Ablation of Atrial Fibrillation The RECIRCUIT Study Hugh Calkins MD 1 Stephan Willems MD Atul Verma. School. co-operation for a . reinforced and constructive educational career. . The task. T. he . Swedish Government. , has presented the National Board of Institutional Care and the National . Agency for Special Needs Education and . 1. 1. http://www.accessdata.fda.gov/cdrh_docs/pdf/P980048b.pdf. The . views and opinions expressed in the following PowerPoint slides are those of . the individual . presenter and should not be attributed to Drug Information Association, Inc. (“DIA”), its directors, officers, employees, volunteers, members, . Field Program Assistant. IR-4 Western Region. . Western Region Ornamental Program. Overview of the program. Participation. Specifics of 2010 and 2011 research. Strengths and challenges. . WR Ornamental Program 2010-11. Disclosures. Andexanet: Designed to Reverse Activity of Factor Xa (FXa) Inhibitors. Study Design. Efficacy Endpoint: Reduction in Anti-FXa Activity. Efficacy Endpoint: Restoration of Thrombin Generation. . . Feb 08/2014. Hanadi. . Alhozali,MBBS,ABIM,FRCPC. Assistant professor consultant internal medicine and Nephrology KAUH/Jeddah. Glomerular- based disease and Renal disease in pregnancy. Objectives. . . Feb 08/2014. Hanadi. . Alhozali,MBBS,ABIM,FRCPC. Assistant professor consultant internal medicine and Nephrology KAUH/Jeddah. Glomerular- based disease and Renal disease in pregnancy. Objectives. Fibrillation. Michelle Tsukamoto . DSR 2 May 9, 2018. PGY 2. 1. Objectives. Discuss which patients with . atrial. fibrillation should be . anticoagulated. for CVA prevention. Learn about different oral anticoagulation options . Fibrillation. Michelle Tsukamoto . DSR 2 May 9, 2018. PGY 2. 1. Objectives. Discuss which patients with . atrial. fibrillation should be . anticoagulated. for CVA prevention. Learn about different oral anticoagulation options . Risks of AF Ablation Procedure. Many Moving Parts . Uninterrupted vs Minimally Interrupted Anticoagulation. Uninterrupted Dabigatran vs Warfarin. DAPPARAF. Dabigatran Ablation Study. RE-CIRCUIT. Multicenter Prospective Study of Uninterrupted Rivaroxaban vs Warfarin. Emily Ellsworth, . PharmD. & Janna Hawthorne, . PharmD. UAMS College of Pharmacy. Objectives:. Explain . the pathophysiological rationale for the off-label utilization of six selected medications: . Geoffrey Barnes, MD, MSc. University of Michigan. @. GBarnesMD. May 14, 2020. Disclosures. Grants: Pfizer/Bristol-Myers Squibb, Blue Cross Blue Shield of Michigan, NHLBI, AHRQ. Consulting: Pfizer/Bristol-Myers Squibb, Janssen, Portola, AMAG Pharmaceuticals. Alfonso Iorio, MD, PhD. Health Information Research Unit & Hemophilia Program. McMaster. University. Canada. Alfonso Iorio. Baxter . (Bayer, . Biogen. Idec, . NovoNordisk. , Pfizer . - No conflicts). double-blind, placebo-controlled study with open-label extension. Atul Deodhar, MD. Oregon Health & Science University. Portland, OR, USA. Key message. Upadacitinib – a JAK1 inhibitor – showed sustained and consistent efficacy over 1 year in AS patients.. - The NOAH-AFNET 6 trial -. Nina Becher, Tobias Toennis, Emanuele Bertaglia, Carina Blomstrom-Lundqvist, Nuno Cabanelas, Melanie Calvert, A John Camm, Gregory Chlouverakis, Gheorghe-Andrei Dan, Wolfgang Dichtl, Hans Christoph Diener, Alexander...